Brainchip Holdings Ltd

BRN

BrainChip Holdings Ltd. engages in the development of software and hardware solutions for artificial intelligence and machine learning applications. The company is headquartered in Sydney, New South Wales and currently employs 78 full-time employees. The company went IPO on 2011-11-09. The Company’s software and hardware accelerated solutions for advanced AI and machine learning applications with a primary focus on the development of its Akida Neuromorphic Processor. The Company’s fully digital, event-based AI processor, Akida, uses neuromorphic principles to mimic the human brain, analyzing only essential sensor inputs at the point of acquisition, processing data with unparalleled efficiency, precision, and economy of energy. Akida enables Edge learning local to the chip, independent of the cloud, reducing latency while improving privacy and data security. Its other products include MetaTF, 2nd Generation akida, Akida1000 reference chip and Akida Enablement Platforms. Akida Enablement Platforms include Akida PCIe Board, Akida Development Kit Shuttle PC, and Akida Development Kit Raspberry Pi.

Elixinol Wellness Limited

EXL

Elixinol Wellness Ltd. engages in the sale of nutraceutical and related hemp products. The company is headquartered in Sydney, New South Wales. The company went IPO on 2018-01-08. The firm is engaged in marketing and selling hemp derived and other plant-based nutraceuticals, skincare and food products. In Australia, it operates a vertically integrated business, which produces, manufactures, and distributes a range of complementary products delivered across four verticals: human nutrition, human wellness, pet wellness and superfood ingredients. These products are sold under brands including Hemp Foods Australia, Mt Elephant and Field Day and are sold through grocery, wholesale, and e-commerce channels. In the Americas, it is engaged in marketing and selling quality Elixinol branded hemp and other plant-derived nutraceutical and skincare products based in Colorado, United States. In the United Kingdom, Japan, Brazil, Mexico and South Africa, branded hemp and other plant-derived products are available to consumers via exclusive distribution and/or trademark and know-how licensing agreements.

Imugene Limited

IMU

Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The company is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.

Mesoblast Limited

MSB

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. The company is headquartered in Melbourne, Victoria and currently employs 83 full-time employees. The company went IPO on 2004-12-16. The company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. The company is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. The company has established commercial partnerships in Europe and China for certain Phase III assets.

Minrex Resources Limited

MRR

MinRex Resources Ltd. engages in the business of exploration and development of gold, base metal, and tin projects in Australia. The company is headquartered in Perth, Western Australia. The company went IPO on 2011-11-11. The firm also has a portfolio of gold and other metals projects in the Lachlan Fold Belt, New South Wales. The firm's tenements package covers over 500 square kilometers (km2) of prospective ground targeting multi-commodity type deposits. Its projects include Marble Bar Lithium Project and Sofala Gold Project. The Marble Bar projects, which cover an area of 71km2 encompassing the Sisters (E45/5871), Garden Creek (E45/5869) and Talga (E45/5873) tenements, are located within a 30 kilometer (km) radius of the Marble Bar town site. The Sisters and Garden Creek tenements cover portions of the fertile Marble Bar Greenstone belt. The Sofala Project is located in the East Lachlan Fold Belt, 180kms Northwest of Sydney, a mining and exploration region which contains several golds, copper-gold and silver deposits.